We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA Approves Brentuximab Vedotin for Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
- Abstract
The article reports on the announcement of the U.S. Food and Drug Administration (FDA) regarding the approval of Brentuximab Vedotin (Adcetris) antibody for the treatment of Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. The drug has been approved for treatment of patients with Hodgkin lymphoma whose disease has progressed after autologous stem cell transplant. It states Brentuximab Vedotin consists of an anti-CD30 antibody conjugated by a plasma-stable linker.
- Subjects
ANTINEOPLASTIC agents; THERAPEUTIC use of monoclonal antibodies; HODGKIN'S disease; LYMPHOMAS; UNITED States. Food &; Drug Administration; DRUG approval
- Publication
Oncology (08909091), 2011, Vol 25, Issue 10, p904
- ISSN
0890-9091
- Publication type
Article